BACKGROUND: There are contradicting reports on the associations between Apolipoprotein E4 (ApoE ε4) and brain outcomes in HIV with some evidence that relationships may be greatest in older age groups. METHODS: We assessed cognition in 76 clinically stable HIV-infected participants over age 60 and genotyped ApoE. Sixty-one of these subjects underwent structural brain magnetic resonance imaging and diffusion tensor imaging. RESULTS: The median age of the participants was 64 years (range: 60-84) and the median estimated duration of HIV infection was 22 years. Apo ε4 carriers (n = 19) were similar to noncarriers (n = 57) in sex (95% vs. 96% male), and education (16.0 vs. 16.2 years) ApoE ε4 carriers demonstrated greater deficits in cognitive performance in the executive domain (P = 0.045) and had reduced fractional anisotropy and increased mean diffusivity throughout large white matter tracts within the brain compared with noncarriers. Tensor-based morphometry analyses revealed ventricular expansion and atrophy in the posterior corpus callosum, thalamus, and brainstem among HIV-infected ApoE ε4 carriers compared with ε4 noncarriers. CONCLUSIONS: In this sample of older HIV-infected individuals, having at least 1 ApoE ε4 allele was associated with decreased cognitive performance in the executive functioning domain, reduced brain white matter integrity, and brain atrophy. Brain atrophy was most prominent in the posterior corpus callosum, thalamus, and brainstem. This pattern of cognitive deficit, atrophy, and damage to white matter integrity was similar to that described in HIV, suggesting an exacerbation of HIV-related pathology; although emergence of other age-associated neurodegenerative disorders cannot be excluded.
BACKGROUND: There are contradicting reports on the associations between Apolipoprotein E4 (ApoE ε4) and brain outcomes in HIV with some evidence that relationships may be greatest in older age groups. METHODS: We assessed cognition in 76 clinically stable HIV-infectedparticipants over age 60 and genotyped ApoE. Sixty-one of these subjects underwent structural brain magnetic resonance imaging and diffusion tensor imaging. RESULTS: The median age of the participants was 64 years (range: 60-84) and the median estimated duration of HIV infection was 22 years. Apo ε4 carriers (n = 19) were similar to noncarriers (n = 57) in sex (95% vs. 96% male), and education (16.0 vs. 16.2 years) ApoE ε4 carriers demonstrated greater deficits in cognitive performance in the executive domain (P = 0.045) and had reduced fractional anisotropy and increased mean diffusivity throughout large white matter tracts within the brain compared with noncarriers. Tensor-based morphometry analyses revealed ventricular expansion and atrophy in the posterior corpus callosum, thalamus, and brainstem among HIV-infectedApoE ε4 carriers compared with ε4 noncarriers. CONCLUSIONS: In this sample of older HIV-infected individuals, having at least 1 ApoE ε4 allele was associated with decreased cognitive performance in the executive functioning domain, reduced brain white matter integrity, and brain atrophy. Brain atrophy was most prominent in the posterior corpus callosum, thalamus, and brainstem. This pattern of cognitive deficit, atrophy, and damage to white matter integrity was similar to that described in HIV, suggesting an exacerbation of HIV-related pathology; although emergence of other age-associated neurodegenerative disorders cannot be excluded.
Authors: Stephanie Chiao; Howard J Rosen; Krista Nicolas; Lauren A Wendelken; Oscar Alcantar; Katherine P Rankin; Bruce Miller; Victor Valcour Journal: AIDS Res Hum Retroviruses Date: 2013-03-20 Impact factor: 2.205
Authors: Virawudh Soontornniyomkij; David J Moore; Ben Gouaux; Benchawanna Soontornniyomkij; Erick T Tatro; Anya Umlauf; Eliezer Masliah; Andrew J Levine; Elyse J Singer; Harry V Vinters; Benjamin B Gelman; Susan Morgello; Mariana Cherner; Igor Grant; Cristian L Achim Journal: AIDS Date: 2012-11-28 Impact factor: 4.177
Authors: Neda Jahanshad; Victor G Valcour; Talia M Nir; Omid Kohannim; Edgar Busovaca; Krista Nicolas; Paul M Thompson Journal: Brain Connect Date: 2012
Authors: Stella E Panos; Charles H Hinkin; Elyse J Singer; April D Thames; Sapna M Patel; Janet S Sinsheimer; A C Del Re; Benjamin B Gelman; Susan Morgello; David J Moore; Andrew J Levine Journal: Neurobehav HIV Med Date: 2013-06-19
Authors: R J Caselli; E M Reiman; D Osborne; J G Hentz; L C Baxter; J L Hernandez; G G Alexander Journal: Neurology Date: 2004-06-08 Impact factor: 9.910
Authors: Talia M Nir; Neda Jahanshad; Edgar Busovaca; Lauren Wendelken; Krista Nicolas; Paul M Thompson; Victor G Valcour Journal: Hum Brain Mapp Date: 2013-01-30 Impact factor: 5.038
Authors: Isaac H Solomon; Sukrutha Chettimada; Vikas Misra; David R Lorenz; Robert J Gorelick; Benjamin B Gelman; Susan Morgello; Dana Gabuzda Journal: Mol Neurobiol Date: 2019-11-05 Impact factor: 5.590
Authors: Katherine M Clifford; Vishal Samboju; Yann Cobigo; Benedetta Milanini; Gabriel A Marx; Joanna M Hellmuth; Howard J Rosen; Joel H Kramer; Isabel E Allen; Victor G Valcour Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Christine Fennema-Notestine; Tricia A Thornton-Wells; Todd Hulgan; Scott Letendre; Ronald J Ellis; Donald R Franklin; Albert M Anderson; Robert K Heaton; Cinnamon S Bloss; Igor Grant; Asha R Kallianpur Journal: Brain Imaging Behav Date: 2020-10 Impact factor: 3.978
Authors: Ana B Martínez-Martínez; Elena Torres-Perez; Nicholas Devanney; Raquel Del Moral; Lance A Johnson; Jose M Arbones-Mainar Journal: Neurobiol Dis Date: 2020-02-19 Impact factor: 5.996